Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Luspatercept is a recombinant fusion protein derived from human activin receptor type IIb (ActRIIb) linked to a protein derived from immunoglobulin G. It binds TGF (transforming growth factor beta) superfamily ligands to reduce SMAD signaling. Inhibition of this family results in increased expression of blood cell precursors and improves parameters associated with ineffective production of red blood cells. Luspatercept is used to treat anemia in adults who are receiving blood transfusions to treat thalassemia (an inherited condition that causes a low number of red blood cells). Luspatercept is also used to treat anemia in adults with certain types of myelodysplastic syndrome.
| Products Name (INN Index) | Pre-Made Luspatercept Biosimilar, Fusion Protein targeting GDF11 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting BMP-11/BMP11/VHO |
|---|---|
| INN Name | luspatercept |
| Target | GDF11 |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 – IGHG1 Fc (Fragment constant) |
| VD LC | Fusion – [ACVR2B (activin A receptor type IIB, ActR-IIB, ActRIIB)]2 – IGHG1 Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Celgene?corporation (Summit USA) / Acceleron?Pharma, Inc (Cambridge UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GDF11 |
| Package |
